<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01069809</url>
  </required_header>
  <id_info>
    <org_study_id>AGS-004-003</org_study_id>
    <secondary_id>HHSN266200600019C</secondary_id>
    <secondary_id>ES-11702</secondary_id>
    <nct_id>NCT01069809</nct_id>
    <nct_alias>NCT00595192</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption</brief_title>
  <official_title>A Randomized, Double-Blind, Phase 2B Study Testing the Efficacy and Safety of AGS-004 on Host Control of HIV Replication During Analytical Treatment Interruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Argos Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Argos Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune&#xD;
      therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the&#xD;
      individuals are both taking antiretroviral therapy (ART) medication and interrupting ART&#xD;
      medication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of AGS-004, an immune&#xD;
      therapy, for HIV-infected individuals. Safety and effectiveness will be tested while the&#xD;
      individuals are both taking antiretroviral therapy (ART) medication and interrupting ART&#xD;
      medication&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the anti-HIV effects of AGS-004 versus Placebo as measured by new HIV Viral Load setpoint after a 12 week Analytical Treatment Interruption</measure>
    <time_frame>38 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate AGS-004 versus Placebo for change in plasma HIV Viral Load levels from the value just before initiation of ART to the value at the end of the 12 week ATI.</measure>
    <time_frame>38 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate AGS-004 versus Placebo for change from Baseline in CD4 T-Cell absolute and percentage values at Week 26 and at the end of Step 4 (for subjects continuing ATI)</measure>
    <time_frame>38 weeks (62 weeks for subjects continuing ATI in Step 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate AGS-004 versus Placebo for effects on HIV viral kinetics during the 12 week ATI, as measured my mean or median levels of plasma HIV Viral Load; assessed throughout and at the end of Step 4 (for subjects continuing ATI)</measure>
    <time_frame>38 weeks (62 weeks for subjects continuing ATI in Step 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate AGS-004 versus Placebo for change from Baseline in TEAEs, clinical laboratory evaluations, and clinical assessments.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate AGS-004 versus Placebo for change in inflammatory markers over treatment period and ATI</measure>
    <time_frame>38 Weeks (62 weeks for subjects continuing ATI in Step 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline in T-cell response.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline of the extent of viral evolution.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study immunogenicity and mechanism of action by evaluating AGS-004 versus Placebo for change from Baseline in the chromosomally integrated viral reservoir.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>AGS-004</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV-1 Immune Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inactive Placebo Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AGS-004</intervention_name>
    <description>HIV-1 Immune Therapy</description>
    <arm_group_label>AGS-004</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive Placebo Injection</description>
    <arm_group_label>Inactive Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females ≥ 18 to 60 years of age.&#xD;
&#xD;
          2. HIV infection.&#xD;
&#xD;
          3. Stable ART regimen for ≥ 3 months prior to Screening.&#xD;
&#xD;
          4. HIV VL level ≤ 400 copies/mL for ≥ 2 months prior to Screening.&#xD;
&#xD;
          5. HIV VL level ≤ 50 copies/mL at Screening.&#xD;
&#xD;
          6. CD4+ T cell count ≥ 450 cells/mm3 at Screening.&#xD;
&#xD;
          7. Pre-ART nadir CD4+ T cell counts ≥ 200 cells/mm³.&#xD;
&#xD;
          8. Availability of an adequate sample of frozen plasma most recently collected (no more&#xD;
             than 90 days and preferably within 30 days) before starting ART.&#xD;
&#xD;
          9. Laboratory values within pre-defined limits at Screening and Eligibility.&#xD;
&#xD;
         10. Negative serum pregnancy test at Screening and Eligibility for females with&#xD;
             reproductive potential, and agreement of all subjects to use a reliable form of&#xD;
             contraception during the study and for 12 weeks after the last dose of study drug.&#xD;
&#xD;
         11. Able and willing to give adequate written informed consent, to communicate effectively&#xD;
             with study personnel, and willing to be compliant with protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HIV-2 antibody positive at Screening Visit.&#xD;
&#xD;
          2. Positive hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody (if&#xD;
             positive HCV antibody, HCV RNA must be negative).&#xD;
&#xD;
          3. Untreated syphilis infection (positive rapid plasma reagin [RPR]).&#xD;
&#xD;
          4. Changes in ART regimen due to virologic breakthrough.&#xD;
&#xD;
          5. History of lymph node irradiation or dissection.&#xD;
&#xD;
          6. Prior use of any HIV immunotherapy or vaccine within 9 months prior to Screening.&#xD;
&#xD;
          7. Prior participation in an AGS-004 clinical study.&#xD;
&#xD;
          8. Treatment interruption of ART for &gt; 1 month since starting the ART from which the&#xD;
             pre-ART plasma sample was drawn.&#xD;
&#xD;
          9. Any acute infection or medical illness within 14 days prior to Screening and&#xD;
             throughout the pre-treatment evaluation phase (Step 1).&#xD;
&#xD;
         10. Initiation of ART during the acute HIV infection stage, if date of infection known&#xD;
             (acute infection defined as &lt; 6 months between date of HIV infection and ART start&#xD;
             date).&#xD;
&#xD;
         11. Pregnancy or breast-feeding.&#xD;
&#xD;
         12. Receipt of any immune modulators or suppressors within 30 days prior to Screening and&#xD;
             throughout the pre-treatment evaluation phase (Step 1).&#xD;
&#xD;
         13. Evidence of hepatic decompensation in cirrhotic subjects: history of ascites, hepatic&#xD;
             encephalopathy, or bleeding esophageal varices, or screening laboratory results of any&#xD;
             of the following:&#xD;
&#xD;
               -  International Normalized Ratio (INR) of ≥ 1.5 X upper limit of normal (ULN);&#xD;
&#xD;
               -  Serum albumin &lt; 3.3 g/dL;&#xD;
&#xD;
               -  Serum total bilirubin &gt; 1.8 X ULN, unless history of Gilbert's disease or deemed&#xD;
                  related to treatment with atazanavir.&#xD;
&#xD;
         14. History or other clinical evidence of significant or unstable cardiac disease (e.g.,&#xD;
             angina, congestive heart failure, recent myocardial infarction, significant&#xD;
             arrhythmia) or clinically significant electrocardiogram (ECG) abnormalities.&#xD;
&#xD;
         15. History of moderate or severe renal impairment (i.e., persistent history of creatinine&#xD;
             clearance &lt; 50 mL/min) or any other renal disorder deemed clinically significant by&#xD;
             the investigator.&#xD;
&#xD;
         16. Prior history of an acquired immunodeficiency syndrome (AIDS) defining condition.&#xD;
&#xD;
         17. History or other evidence of severe illness, malignancy, immunodeficiency other than&#xD;
             HIV, or any other condition that would make the subject unsuitable for the study in&#xD;
             the opinion of the investigator.&#xD;
&#xD;
         18. Known allergy or sensitivity to the components of the investigational immunotherapy.&#xD;
&#xD;
         19. Active drug or alcohol use or dependence that would interfere with adherence to study&#xD;
             requirements in the opinion of the investigator.&#xD;
&#xD;
         20. Use of systemic corticosteroids and use of topical steroids over a total area&#xD;
             exceeding 15 cm² within 30 days prior to Screening.&#xD;
&#xD;
         21. Any investigational antiretroviral agents or use of a CCR5 inhibitor at Screening.&#xD;
&#xD;
         22. Active autoimmune disease or condition.&#xD;
&#xD;
         23. Participation in another investigational clinical study within the previous 30 days or&#xD;
             use of investigational agents.&#xD;
&#xD;
         24. Body weight less than 30 kg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffery Jacobson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drexel University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCDavis Research Office at CARES</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi &amp; North Central Bronx Hospitals</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Clinical Trials Unit</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Infectious Disease and HIV Medicine Partnership Comprehensive Care Practice</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>191002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 816</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique médicale l'Actuel</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L4P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Médical du Quartier Latin</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2L5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Chest Institute, Immunodeficiency Dept.</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.argostherapeutics.com/</url>
    <description>Sponsor Website</description>
  </link>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>February 16, 2010</study_first_submitted>
  <study_first_submitted_qc>February 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2010</study_first_posted>
  <last_update_submitted>January 23, 2017</last_update_submitted>
  <last_update_submitted_qc>January 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

